bioRxivBiochemistryPreprint
Dual Enzyme Inhibition Strategy for Type 2 Diabetes: Targeting LDH-A and α-Amylase with Flavonoid-Acarbose Combinations
Abstract
Diabetes mellitus is a complex and widespread disease affecting over 100 million people globally. It increases the risk of severe complications such as heart attack, neuropathy, and retinopathy. While various therapies aim to manage the disease, one effective approach involves reducing the activity of starch-degrading enzymes, such as -amylase, to limit the amount of free glucose in the body. Another target is lactate dehydrogenase-A (LDH-A), an enzyme involved in gluconeogenesis through its role in generating pyruvate. In recent years, flavonoids have gained significant attention for their potential to inhibit both -amylase and LDH-A. This study investigates the flavonoids present in green and black tea for their ability to inhibit porcine pancreatic amylase (PPA) and LDH-A, comparing their efficacy to established anti-diabetic drugs such as Acarbose and Metformin using computational methods. In vitro experiments demonstrated that Quercetin shows potent anti-LDHA-A activity with an IC50 of 4.161 {micro}M. Quercetin inhibits PPA with an IC50 value of 20 {micro}M, while eriodyctiol and myricetin exhibit IC50 values of 22 {micro}M and 24 {micro}M, respectively. Additionally, quercetin was found to synergistically enhance the inhibitory effects of the commonly used -amylase inhibitor, Acarbose.
- research focus: drug response / drug discovery
- research focus: differential expression
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis
Santosh Basnet, Madhav Prasad Ghimire, … Achyut Adhikari·bioRxiv·Sep 26, 2022
- Inhibitory and in silico molecular docking of Xeroderris stuhlmannii (Taub.) Mendonca & E.P. Sousa phytochemical compounds on human α-glucosidases
B. Nyathi, J. T. Bvunzawabaya, … F. Rwere·bioRxiv·Sep 16, 2022
- Identification of Potential EGFR Inhibitors for Type 2 Diabetes and Pancreatic Cancer Treatment: A Computational Approach
Ricardo Cuéllar Romero·bioRxiv·Sep 5, 2023
- In-vitro and Insilico screening platform for the identification of aldose reductase inhibitors for antidiabetic lead compounds from Abutilon Indicum (L.)
- Elucidation of α-glucosidase inhibitory activity and UHPLC-ESI-QTOF-MS based metabolic profiling of endophytic fungi Alternaria sp. BRN05. isolated from seeds of Swietenia macrophylla King.
Piyush Kumar, Sai Anand Kannakazhi Kantari, … Malleswara Dharanikota·Frontiers in Fungal BiologyPeer-reviewed·Jan 28, 2025
- Antidiabetic effect of 1-deazapurines derivatives with alpha-glucosidase Enzyme: A molecular tools approach
F. BOUKLI HACENE, S. A. Cherrak, … S. Ghalem·bioRxiv·Feb 20, 2024